People · Operator
Named in public records as an officer, director or promoter · active 2010–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fate Therapeutics Inc | — | Biotechnology | Series C | $241.3M | $2.0B | 2016 |
| BIND Biosciences Inc | — | Biotechnology | Series B | $51.4M | $345.2M | 2010 |
| Primmune Therapeutics, Inc. | — | Pharmaceuticals | Series A | $20.1M | $350.3M | 2020 |
AMIR S. NASHAT at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside AMIR S. NASHAT on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Bryan Roberts | 1 | 18 |
| Michael Lee | 1 | 15 |
| Peter Barton Hutt | 1 | 14 |
| Robert S Langer | 1 | 14 |
| Amir Nashat | 1 | 14 |
| Noubar Afeyan | 1 | 9 |
| James Wright | 1 | 9 |
| Charles McDermott | 1 | 8 |
| Robert Epstein | 1 | 8 |
| Carl Weissman | 1 | 8 |
| Scott Minick | 1 | 7 |
| Daniel S. Lynch | 1 | 6 |
| Bryan E. Roberts | 1 | 6 |
| PAUL Grayson | 1 | 5 |
| Robert T. Nelsen | 1 | 5 |
| John Mendlein | 1 | 4 |
| Omid Farokhzad | 1 | 4 |
| William Rastetter | 1 | 4 |
| Andrea Franz | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.